Atara Biotherapeutics has sold its marketing rights to Ebvallo (tabelecleucel) in North America, Asia Pacific, and Latin America to Pierre Fabre Laboratories, in a deal worth over $640m.
Ebvallo is an off-the-shelf, allogeneic T-cell immunotherapy, which has been approved as monotherapy by the European Commission (EC) for treating patients ages two years and above with Epstein‑Barr virus-positive post‑transplant lymphoproliferative disease (EBV+ PTLD).
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The additional Ebvallo rights agreement grants Atara $30m in upfront payment, up to $100m in regulatory milestone-based payments and double-digit tiered royalties on net sales. The upfront payment also includes the cost for the initial inventory purchase for Ebvallo, as per the 3 November press release.
Additionally, Pierre Fabre will also reimburse Atara for Ebvallo’s global development costs. Atara plans to submit the biologics license application (BLA) for Ebvallo for treating EBV+ PTLD in Q2 2024. Following the BLA approval, Atara will transfer the BLA along with the associated manufacturing, clinical, and regulatory activities to Pierre Fabre.
In 2021, the French company acquired Ebvallo’s marketing rights in Europe, the Middle East, Africa, and other select emerging markets. At the time, Pierre Fabre announced it would pay $45m in upfront cost, up to $320m in milestone-based payments, and double-digit tiered royalties as a percentage of net sales.
“Pierre Fabre Laboratories have made oncology their top priority in medical care. Since 2019, we have almost tripled our revenues in this therapeutic field, and we expect to pass the €500m ($535.8m) bar this year,” said Eric Ducournau, CEO of Pierre Fabre Laboratories.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This expansion of our partnership with Atara will allow us to make a first step in the US, by far the largest oncology market in the world, and to reach even more patients in need for innovative treatments.”
In September, the French company partnered with HitGen’s UK subsidiary Vernalis to identify and develop multiple oncology drugs. In April, it partnered with Scorpion Therapeutics to co-develop two epidermal growth factor receptor (EGFR) inhibitors that target EGFR mutations in non-small cell lung cancer (NSCLC).
